What is ENDUROBOL (GW-501516)?

ENDUROBOL (GW501516 or GSK-516) is a PPARδ receptor agonist that was previously investigated for drug use.

ENDUROBOL is a selective agonist with high affinity and it is very potent. Various studies on this PPAR receptor in lab indicates that it regulates the various proteins that the body uses for energy.

ENDUROBOL can help to reduce and even reverse various problems in men who are obese or that have symptoms of pre-diabetes due to problems with their metabolism. The use of GW-501516 is viable treatment for reducing obesity and various conditions that are linked to it.

How it works?

ENDUROBOL is a selective agonist (activator) of the PPARδ receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ.

It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in human.

Dosages and S estion

Recommended maximum dose ENDUROBOL is 10 mg per day but many people use as much as 20 mg per day to burn as much fat as they can in in the 8 week cycle.